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Abstract
Background: The proteasome inhibitor bortezomib has shown impressive clinical activity alone
and in combination with conventional and other novel agents for the treatment of multiple
myeloma (MM) and some solid cancers. Although bortezomib is known to be a selective
proteasome inhibitor, the downstream mechanisms of cytotoxicity and drug resistance are poorly
understood.
Methods: Proteasome activity, intracellular glutathione (GSH) and ROS levels, as well as activities
of GSH synthesis enzymes were measured using spectrophotometric methods. Cell death was
analyzed using flow cytometry and caspase activity assay. The expression level of GSH synthesis
enzymes were measured using real-time RT-PCR.
Results: At concentrations that effectively inhibited proteasome activity, bortezomib induced
apoptosis in FRO cells, but not in ARO cells. Bortezomib elevated the amount of glutathione (GSH)
and the treatment with bortezomib increased the level of mRNA for GCL, a rate-limiting enzyme
in glutathione synthesis. Furthermore, depletion of GSH increases apoptosis induced by
bortezomib, in contrast, repletion of GSH decreases bortezomib-mediated cell death.
Conclusion:  GSH protects cells from proteasome inhibition-induced oxidative stress and
glutathione-dependent redox system might play an important role in the sensitivity to proteasome
inhibition-induced apoptosis.
Background
Protein degradation is crucial for controlling the availabil-
ity of regulatory proteins in the cell. The ubiquitin-protea-
some system (UPS) represents the major degradation
pathway for proteins involved in the regulation of cell sur-
vival, proliferation, apoptosis and other critical cellular
functions [1]. UPS also has a critical role in the selective
removal of mutant, damaged, and misfolded proteins.
Based on these unique properties of the UPS, the proteas-
ome pathway has recently emerged as an attractive target
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for the development of anti-cancer agents. Proteasome
inhibitors represent a diverse group of agents that target
the 20S proteasome, a component of the UPS that is
responsible for the degradation of unwanted cellular pro-
teins [2]. Although the mechanism by which proteasome
inhibitors kill neoplastic cells is not known with certainty,
it has been shown that proteasome inhibitors interfere
with key steps of tumor cell regulation, leading to a block
of proliferation and death of neoplastic cells both in vitro
and in vivo, thus emerging as a new class of anticancer
drugs. Experimental and clinical support for this thera-
peutic strategy has been provided by bortezomib [3,4].
The involvement of oxidative stress is supported by emerg-
ing studies showing that reactive oxygen species (ROS) gen-
eration plays a critical role in the initiation of the
bortezomib-induced apoptotic cascade [5]. Oxidative stress
is a complex and dynamic situation characterized by an
imbalance between the productions of ROS and the availa-
bility and action of antioxidants. Oxidative stress has tradi-
tionally been considered in negative terms due to its
association with macromolecular damage and triggering
cell death through the effects of oxidants on signal trans-
duction pathways, including the activation of sphingomy-
elinase, caspases and cathepsin D [6-10]. Generation of
ROS is now considered to be the early and critical events for
the initiation of bortezomib-induced apoptotic signaling in
some human cancer cell lines [5,11-13]. One of the major
mechanisms by which cells protect themselves against oxi-
dative stress is upregulation of a wide range of antioxidant
genes. Among intracellular antioxidant molecules, reduced
glutathione (GSH) is the most abundant intracellular non-
protein thiol in cells. By keeping the cellular environment
in a reduced state, GSH functions in the removal of poten-
tially toxic electrophiles and metals, thereby protecting cells
from toxic oxygen products [14]. Furthermore, GSH exhib-
its a large panel of actions in controlling gene expression,
apoptosis mechanisms, or membrane transport [15].
Therefore, cells tightly regulate the synthesis, utilization
and export of GSH. L-S,R-buthionine sulfoximine (BSO) is
a potent specific inhibitor of γ-glutamylcysteine synthetase,
the rate-limiting enzyme in GSH biosynthesis, and has
been used to deplete intracellular GSH and to reverse drug
resistance in tumor cells [16]. GSH has for long been
known a chemoresistance factor in cancer cells [17].
Several studies have suggested that UPS is involved in the
regulation of anti-oxidants, such as catalase, heme oxyge-
nase-1 (HO-1), copper/zinc-superoxide dismutase and γ-
GCS [18-21]. The relationship between intracellular GSH
level and proteasome inhibition-induced apoptosis still
remains to be defined. To establish the contribution of
ROS to bortezomib-induced thyroid cancer cell death, we
performed a comparative kinetic analysis of ROS levels in
ARO and FRO cells. In addition, we modulated the intra-
cellular GSH level by depletion/repletion to study the role
of this variable in cell sensitivity to treatment with borte-
zomib in human thyroid cancer cells. We found that ROS
generation played a critical role in bortezomib-mediated
apoptosis in thyroid cancer cells. Our results indicate that
GSH depletion could be useful to increase the therapeutic
efficacy of thyroid cancer treatment by bortezomib.
Methods
Multiple undifferentiated thyroid cancer cell lines
The ARO81-1 (simply ARO) and FRO82-1 (simply FRO)
cell lines were initially obtained from Dr. James A. Fagin
(University of Cincinnati College of Medicine, Cincinnati,
OH) and provided to us by Dr. Shunichi Yamashita
(Nagasaki University Graduate School of Biomedical Sci-
ences, Japan). KTC2 cell line was generously provided by
Dr. Junichi Kurebayashi (Kawasaki Medical School,
Japan). 8305C cells were obtained from the European
Collection of Animal Cell Cultures. All cell lines were
maintained in RMPI 1640 (Sigma-Aldrich, Saint Louis,
MO) supplemented with 10% fetal bovine serum (FBS,
Sigma-Aldrich, Saint Louis, MO).
Chemicals
Bortezomib was obtained from Millennium Pharmaceuti-
cals Inc. (Cambridge, MA) and was dissolved in dimethyl
sulfoxide (DMSO) as a stock solution. Specific GSH syn-
thesis inhibitor (BSO) and glutathione were from Sigma-
Aldrich. N-Acetyl-L-cysteine (L-NAC; Calbiochem, San
Diego, CA) was prepared in sterile water immediately
before use.
20S proteasome activity assay
Cytosolic extracts (without protease inhibitors) were used
to measure proteasome activity using 20S proteasome
assay kit (Chemicon International, Temecula, CA) follow-
ing the manufacturer's instructions. The assay is based on
detection of the fluorophore 7-amino-4-methylcoumarin
(AMC) after cleavage from the labeled substrate LLVY-
AMC. Levels of released AMC were measured using an
excitation wavelength of 380 nm and an emission wave-
length of 460 nm with an automatic multi-well plate
reader. The relative activity was standardized by protein
concentration, determined using Coomassie Protein
Assay Reagent (Pierce, Rockford, IL).
Detection of cell death
For cell death assays, cells were washed twice in phos-
phate-buffered saline and then stained with Annexin V-
FITC (Biovision, Mountainview, CA) and propidium
iodide (PI, Sigma-Aldrich) according to the manufac-
turer's instructions. After staining with annexin V-FITC
and PI, samples were analyzed by fluorescence-activated
cell scanner (FACScan) flow cytometer (Becton Dickin-
son, Franklin Lakes, NJ).BMC Cancer 2009, 9:56 http://www.biomedcentral.com/1471-2407/9/56
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Caspase-3 activity assay
For caspases-3 enzymatic assays, 50 μg of whole cell
extract were added to reaction buffer containing 25 mM
HEPES (pH 7.5), 4 mM CHAPS, 1 mM DTT, 1 mM PMSF,
2 μg/ml aprotinin, 1 μg/ml leupeptin, and 2 μg/ml pep-
statin, to achieve a total reaction volume of 500 μl. Ac-
DEVD-AMC (Ac-Asp-Glu-Val-Asp-7-amino-4-methylcou-
marin; Alexis Biochemicals, San Diego, CA) was added to
the mixture at a concentration of 100 μM and incubated
for 1 hour at 37°C. Cleavage of the substrate was meas-
ured by fluorescence spectrometer (HTS 7000, Perkin
Elmer, Boston, MA) using an excitation and emission
wavelength of 360 nm and 465 nm, respectively. The
activities were expressed as fluorescence increase per μg of
protein.
Measurement of intracellular ROS levels
The average level of intracellular ROS in thyroid cancer
cells was evaluated in cells loaded with the redox-sensitive
dye DCFH-DA (Molecular Probes, OR). Cells were
washed twice in a phosphate-buffered saline (PBS) and
stained in the dark for 30 min with 20 μM DCFH-DA and
harvested. Cells were dissolved with 1% Triton X-100, and
fluorescence was measured at an excitation wavelength of
485 nm and an emission wavelength using a fluorescence
spectrometer (HTS 7000, Perkin Elmer, Boston, MA). A
duplicate culture with the same treatments was used to
determine the total protein levels. The ROS levels were
expressed as arbitrary unit/mg protein, then as the per-
centage of control.
Measurement of glutathione levels
Cells were scraped and collected by centrifugation. The
cell pellet was resuspended in 5% metaphosphoric acid
(Sigma-Aldrich) and supernatant was collected for deter-
mining total glutathione and oxidized glutathione
(GSSG) concentrations using a commercial kit according
to the manufacturer's protocol (glutathione assay kit;
Trevigen Inc., Gaithersburg, MD). Reduced glutathione
(GSH) concentration was obtained by subtracting the oxi-
dized from the total concentration. A duplicate culture
with the same treatments was used to determine the total
protein levels. The GSH or GSSG levels were expressed as
nmol/mg of protein and then as the percentage of control.
GSH synthesis enzyme activity assays
Cells were collected, homogenized, and centrifuged at
12000 × g for 30 min. The glutamate cysteine ligase (GCL)
and glutathione synthetase (GS) enzyme activities were
determined by the formation of ADP using a coupled
assay with pyruvate kinase and lactate dehydrogenase. The
GCL reaction mixture (final volume, 200 μl) contained
100 mM Tris-HCl buffer (pH 8.2), 20 mM MgCl2, 150
mM KCl, 10 mM L-glutamate, 10 mM L-cysteine, 5 mM
ATP, 2 mM EDTA, 0.2 mM NADH, 2 mM phosphoe-
nolpyruvate, 2 units of pyruvate kinase and 2 units of lac-
tate dehydrogenase. The GS reaction mixture contained
100 mM Tris-HCl buffer (pH 8.2), 20 mM MgCl2, 50 mM
KCl, 10 mM ATP, 2 mM EDTA, 5 mM glycine, 5 mM L-γ-
glutamyl-L-α-aminobutyrate, 0.2 mM NADH, 0.5 mM
phosphoenolpyruvate, 2 units of pyruvate kinase, and 2
units of lactate dehydrogenase. The reaction was initiated
by adding 100 μg of protein extract, and the absorbance at
340 nm was monitored. The specific activity is expressed
as units/mg of protein and then as a percentage of control.
Real time RT-PCR analysis
Real time RT-PCR was performed to determine the mRNA
levels of GCL and GS. Total RNA was isolated from cul-
tures using Trizol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer's protocol. RT and real-
time PCR was performed as previously described [22]. For
GCLC, the forward primer was 5'-CAAGGACGTTCT-
CAAGTGGG-3' and the reverse was 5'-CATACTCT-
GGTCTCCAAAGG-3'. For GS, the forward primer was 5'-
ATGGACATGGTGAGCAACCAG-3' and reverse was 5'-
CTTGACTCCAGCATACAAGC-3'. For β-actin, the forward
primer was 5'-GAGACCTTCAACACCCCAGCC-3' and the
reverse was 5'-GGATCTTCATGAGGTAGTCAG-3'.
Data analysis
Statistical difference were evaluated using ANOVA with
Dunnett's post hoc test and considered significant at P <
0.05.
Results
Effect of bortezomib on ROS generation in thyroid cancer 
cells
In our recent studies, we had demonstrated that proteas-
ome inhibitors exhibited significant cytotoxicity against
human undifferentiated thyroid cancer cells [22]. Consist-
ent with our previous report [22], FRO and KTC2 cells were
sensitive to bortezomib treatment with IC50 values in the
range of 25–50 nM (Figure 1A). ARO and 8305C cells dem-
onstrated limited cell toxicity, less than 20% cell death was
observed even in the presence of high concentration of
bortezomib (Figure 1A). Bortezomib was a potent death
inducer in FRO and KTC2 cells, fewer cells were alive after
treatment for 36–48 hours (Figure 1B). On the other hand,
Bortezomib-induced apoptotic death was delayed in ARO
or 8305C cells. Prior to treatment for 24 hours, little cell
death was observed in these tumor cells. Moreover, almost
half of cells survived even after exposure for 48 hours (Fig-
ure 1B). The cell death effects of bortezomib in thyroid can-
cer cells were confirmed by caspase-3 activity assay (Figure
1C). Bortezomib quickly suppressed proteasome activity,
about 50% suppression was observed upon exposure to
bortezomib for half hour (Figure 1D). The suppression
peaked at 2 hours and remained within 24 hours (Figure
1D). Bortezomib induced almost equal suppression in allBMC Cancer 2009, 9:56 http://www.biomedcentral.com/1471-2407/9/56
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Generation of ROS during bortezomib treatment Figure 1
Generation of ROS during bortezomib treatment. A, Cells were treated with the indicated concentration of borte-
zomib for 24 hours and apoptotic cells were analyzed. B, Cells were treated with 50 nM bortezomib for the indicated time, 
apoptotic cells were analyzed using annexin V/PI double staining and subsequent flow cytometry. C, Cells were treated with 50 
nM bortezomib for 8 hours and intracellular caspase 3 activity was measured. D-E, Cells were treated with 50 nM bortezomib 
for the indicated time, proteasome activity (D) and production of ROS (E) were analyzed. *, P< 0.05; ** P < 0.001 vs vehicle (A, 
C) or 0 hour treatment (B, D-E).
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these thyroid cancer cells (Figure 1D), suggesting that inhi-
bition of proteasome activity per se is not sufficient to
induce cell death. We then investigated whether proteas-
ome inhibition affect the generation of ROS in thyroid can-
cer cells. Exposure to bortezomib caused an increase in ROS
levels in FRO thyroid cancer cells as measured by DCF flu-
orescence. Without bortezomib treatment, there were no
significant differences in ROS levels among these thyroid
cancer cells (data not shown). The relative levels of ROS
were elevated as early as 4–8 hours after exposure to borte-
zomib, peaked at 24 hours and gradually declined in FRO
cells (Figure 1E). Similar results were also observed in KTC2
cells (Figure 1E), which also demonstrated very sensitive to
bortezomib-induced apoptosis. ARO and 8305C cells were
relatively refractory to bortezomib-mediated ROS release
(Figure 1E). In these tumor cells, no significant DCF fluo-
rescence was detected prior to 8–12 hours and ROS produc-
tion was visualized 24–36 hours post-bortezomib
treatment (Figure 1E). Maintaining low levels of ROS in
response to bortezomib until late times after treatment,
suggesting that bortezomib was not an effective inducer of
ROS production or elevation of intracellular antioxidants
quickly scavenged the ROS in these tumor cells.
Effects of bortezomib on intracellular glutathione level
Distinct ROS generation patterns prompted us to compare
the intracellular levels of the reducing agent GSH, the
most abundant intracellular antioxidant, in thyroid can-
cer cells. Without bortezomib treatment, there were no
significant differences in GSH levels among the panel of
thyroid cancer cells (30–40 nmol/mg protein). With bort-
ezomib treatment, no obvious alterations in GSH levels
were observed in FRO and KTC2 cells at 4–8 hours, a sig-
nificant fall was demonstrated starting at 12 hours after
exposure (Figure 2A). ARO and 8305C cells had levels of
GSH that were even higher than vehicle-treated controls at
8 hours after exposure. The amount of reduced GSH was
further increased at 12–16 hours, and peaked at about 24
hours after exposure (Figure 2A). Since the increase in
reduced GSH could be derived from reduction of oxidized
glutathione (GSSG) by glutathione reductase or from de
novo synthesis [23], we investigated the amount of GSSG
upon exposure to proteasome. No marked alteration in
GSSG amount was observed in FRO and KTC2 cells within
24 hours (Figure 2B). In ARO and 8305C cells, the
amount of GSSG was even elevated at 16–24 hours of
bortezomib exposure and restored to the basal level after
36 hours (Figure 2B). As the amount of GSSG was not
decreased, but even elevated at some time points in ARO
and 8305C cells, it is suggested that reduction of GSSG
was not responsible for GSH elevation in these cells.
Bortezomib induces expression of GCLC, the catalytic 
subunit of γ-GCS
GSH is synthesized by glutamate cysteine ligase (GCL)
and glutathione synthetase (GS). GCL is also known as γ-
glutamylcysteine synthetase (γ-GCS), a rate-limiting
enzyme in glutathione synthesis. To determine the molec-
ular details of glutathione elevation upon bortezomib
treatment, we went on to assay the activity of two GSH
synthetic enzymes. Alteration of GCL enzymatic activity
was not observed in FRO or KTC2 cells (Figure 3A). How-
ever, GCL enzymatic activity was significantly increased in
ARO or 8305C cells at 8 hours and after exposure to bort-
ezomib, and peaked at 16–24 hours (Figure 3A). On the
other hand, GS enzymatic activity was not changed in any
cells (Figure 3B). Furthermore, after treatment with borte-
zomib, GCLC (the catalytic subunit for GCL) mRNA
expression was significantly increased at 4–8 hours after
treatment with bortezomib in ARO and 8305C cells (Fig-
ure 3C). The levels of mRNA for GCLC were also slightly
increased in FRO and KTC2 cells at 16–24 hours, but to a
much lesser extent than in ARO or 8305C cells (Figure
3C). The GS mRNA levels were not changed after borte-
zomib treatment in any treatment group (Figure 3D).
Because GCL is the rate-limiting enzyme in GSH synthe-
sis, thus increased GCLC transcription and GCL enzy-
matic activity might be responsible for the increased
synthesis of GSH in these tumor cells.
Effects of antioxidants on bortezomib-induced apoptotic 
death in thyroid cancer cells
Because bortezomib treatment led to the enhancement of
ROS generation prior to obvious apoptotic effects, it is
possible that alterations in the cellular superoxidant state
could play a role in the sensitivity to bortezomib-induced
apoptosis. To examine whether elevated ROS is crucial for
bortezomib-induced apoptosis in thyroid cancer cells, the
cell-permeable superoxide scavenger tiron was utilized to
perturb the bortezomib-induced ROS generation and
then to examine the consequent events. Cotreatment with
1 mM tiron for 24 hours resulted in the complete abroga-
tion of bortezomib-induced generation of ROS (Figure
4A). Abolishment of intracellular superoxide by tiron pro-
vided significant protection against apoptosis caused by
bortezomib (Figure 4B). To clarify the contribution of
intracellular glutathione to ROS suppression, we exam-
ined the effect of pretreatment with GSH, or N-acetyl-L-
cysteine (NAC), which is a precursor of glutathione and
elevates glutathione contents. Glutathione content was
significantly elevated by treatment with 10 mM GSH for 4
hours or 10 mM NAC for 24 hours (Figure 4C). Pretreat-
ment with GSH or NAC abrogated the decrease in intrac-
ellular GSH level mediated by bortezomib in FRO and
KTC2 cells (Figure 4C). Bortezomib alone significantly
increased the intracellular GSH in ARO and 8305C cells,
whereas GSH or NAC pretreatment had little effect (Figure
4C). Pretreatment with GSH or NAC significantly sup-
pressed bortezomib-induced ROS generation (Figure 4D)
and provided significant protection against apoptosis
caused by bortezomib in FRO and KTC2 cells (Figure 4E).
Minor apoptotic cells were observed in ARO and 8305CBMC Cancer 2009, 9:56 http://www.biomedcentral.com/1471-2407/9/56
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Alteration of glutathione upon bortezomib exposure Figure 2
Alteration of glutathione upon bortezomib exposure. Cells were treated with 50 nM bortezomib for the indicated 
time, intracellular GSH (A) and GSSG (B) levels were measured. ** P < 0.001 vs 0 hour treatment.
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Effects of bortezomib on the synthesis of glutathione Figure 3
Effects of bortezomib on the synthesis of glutathione. Cells were treated with 50 nM bortezomib for the indicated 
time, intracellular GCL (A) and GS (B) activity were measured. In the parallel experiments, GCLC (C) and GS (D) mRNA lev-
els were investigated using real time PCR. *, P< 0.05; ** P < 0.001 vs 0 hour treatment.
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Effects of antioxidants on the bortezomib-induced cell death Figure 4
Effects of antioxidants on the bortezomib-induced cell death. Cells were treated with 50 nM bortezomib together 
with or without tiron for 24 hours, and production of ROS (A) and apoptotic cell (B) were analyzed. C, cells were pretreated 
with vehicle, GSH or NAC, sequentially treated with 50 nM bortezomib for additional 24 hours, and then intracellular GSH 
levels were measured. D, cells were treated as in C, and production of ROS was investigated. E, cells were treated as in C, and 
apoptotic cells were analyzed. *, P< 0.05; ** P < 0.001.
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cells, and GSH or NAC pretreatment did not provide fur-
ther protection (Figure 4E).
Depletion of reduced glutathione level sensitizes thyroid 
cancer cells towards bortezomib-mediated apoptosis
To further explore whether modulation of GSH level
would modify the cell response to apoptosis induced by
bortezomib, buthionine sulfoximine (BSO), an irreversi-
ble inhibitor of GCL was incubated prior to bortezomib
treatment. Following a 4-hour treatment with 0.2 mM
BSO, the intracellular GSH level was markedly reduced
(Figure 5A). BSO treatment increased apoptosis induction
both in sensitive and insensitive cells (Figure 5B). 10 mM
GSH monoethyl ester was further utilized to replete with
intracellular GSH level after BSO treatment. Following a
3-hour GSH monoethyl ester treatment, an -2 to 3-fold
increase in intracellular GSH level was detected (Figure
5A). When cells were supplement with exogenous GSH
monoethyl ester with BSO also present, GSH monoethyl
ester treatment reversed the effect of BSO on apoptosis
induced by proteasome inhibition (Figure 5B).
Discussion
The proteasome is responsible for the degradation of most
cellular proteins and is therefore critical to the regulation
of many processes, including cell cycle progression and
apoptosis. The role of the proteasome in regulating the
growth and survival of tumor cells makes it an attractive
therapeutic target. Proteasome inhibitors have emerged as
a new group of chemotherapeutic agents for human can-
cer[1]. Bortezomib is a small molecule proteasome inhib-
itor that has shown antitumoral activity in a number of
cell types and is currently undergoing clinical trials. The
mechanisms underlying antitumoral effects of borte-
zomib are not totally defined. In the present work, we
show that ROS generation is implicated in bortezomib-
induced thyroid cancer cell death. The inhibition of ROS
significantly suppressed bortezomib-induced apoptosis in
sensitive cells. In support of the role of ROS in borte-
zomib-induced apoptosis, we found that ROS were tran-
siently and weakly induced in less sensitive cells.
Furthermore, depletion of intracellular GSH sensitized
thyroid cancer cells to bortezomib-induced apoptosis,
whereas repletion of GSH inhibited bortezomib-mediated
thyroid cancer cell death.
ROS are now thought to be involved in several cellular
mechanisms including apoptosis [24]. Studies in a variety
of tumor cell types have suggested that cancer chemother-
apy drugs induce apoptosis in part by generating endog-
enous oxidants [25]. Increasing evidence now
demonstrates that the redox status of cells is an important
factor in determining whether tumor cells can withstand
chemotherapy [26]. Although there are multiple potential
detoxification mechanisms that affect the efficacy of
chemotherapeutic drugs and confer drug resistance to tar-
geted cells, GSH has a prominent role in resistance to
chemotherapy [27]. GSH and its associated enzymes play
a critical role in the cell susceptibility to the cytotoxic
effect of alkylating agents, doxorubicin, cisplatin and
nitrosoureas [28]. It has been shown that for these drugs,
increased cellular GSH levels can confer cells resistance
and decreased cellular GSH levels can sensitize cells to the
killing effects [29,30]. Interest for clinical trials in modu-
lating GSH level to increase tumor cell response to anti-
cancer drug treatment is still growing [31,32].
Generation of ROS is now considered to be the early and
critical events for the initiation of bortezomib-induced
apoptotic signaling in some human cancer cell lines
[5,11-13]. It has also been reported that GSH could not
inhibit bortezomib-induced cell death in some lung can-
cer cell lines [33]. In this study, we propose that produc-
Effects of intracellular GSH on the bortezomib-induced cell  death Figure 5
Effects of intracellular GSH on the bortezomib-
induced cell death. Cells were pretreated with BSO alone 
or BSO and GSH monoethyl ester, 24 hours later after 
sequential treatment with vehicle or bortezomib, intracellu-
lar GSH level (A) and apoptotic cells (B) were analyzed. *, P< 
0.05; ** P < 0.001.
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tion of ROS is associated with bortezomib-induced
apoptosis in thyroid cancer cells. Although the reported
results to date may seem contradictory, they may more
likely represent tissue and cell type-specific differences.
Our results indicate that bortezomib induces the produc-
tion of oxygen species, which participate in signaling,
intracellular anti-oxidant defense systems to quench some
of these ROS, reducing bortezomib-induced apoptotic sig-
naling and therefore drastically reducing the frequency of
apoptosis. GSH is the most abundant cellular thiol and
plays a central role in maintaining cellular redox status
and increases in GSH levels would be expected to reduce
ROS levels and antagonize apoptotic signals [34]. In the
current study, we found that bortezomib induced quick
increase in ROS production, and subsequent decrease in
GSH levels in sensitive thyroid cancer FRO and KTC2
cells. On the other hand, in insensitive thyroid ARO and
8305C cells, bortezomib had little effect on ROS genera-
tion and increased the intracellular GSH level within 24
hours. During this period, it is intriguing that bortezomib
induced upregulation of GCLC and activation of GCL in
ARO and 8305C cells, whereas had little effect in FRO and
KTC2 cells. Although the thyroid origin of ARO cells has
been recently questioned [35], our results suggest that
ROS generation might be implicated in the cytotoxic
response of some cancer cells to bortezomib and ability of
cancer cells to induce GCL and subsequent GSH levels,
thereby scavenging ROS is, at least in part, involved the
cytotoxic responses to bortezomib exposure.
Conclusion
ROS generation is implicated in cytotoxic responses of
thyroid cancer cells to bortezomib. Sensitivity of thyroid
cancer cells to bortezomib is associated with the inability
to induce GSH synthesis and subsequent GSH levels,
thereby quenching ROS.
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